The growth of the EPS is critical in understanding the current valuation of MorphoSys AG. The EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been 71.30 % over the last twelve months. EPS growth is a vital measure of execution of the strategy for MorphoSys AG since it indicates how well the business is allocating resources to benefit shareholders.
MorphoSys AG is in the biotechnology industry and trades as part of the healthcare sector. MorphoSys AG engages in the development of therapeutic antibodies to cure inflammatory and autoimmune diseases, as well as cancer and infectious diseases. The company operates through two business segments; Partnered Discovery and Proprietary Development.
Previous Intraday Performance:
The MOR shares had a previous change of -6.18% which opened at 29.36 and closed at 28.22. It moved to an intraday high of 29.36 and a low of 27.89.
Over the last five trading days, MOR shares returned -1.33% and in the past 30 trading days it returned 19.98%. Over three months, it changed -4.34%. In one year it has changed 7.26% and within that year its 52-week high was 35.90 and its 52-week low was 21.75. MOR stock is 29.75% above its 52 Week Low.
Our calculations result in a 200 day moving average of 28.06 and a 50 day moving average of 26.10. Right now, MOR stock is trading 0.57% above its 200 day moving average and may be a good opportunity to buy.
The company has a market cap of $3.6b with 126.0m shares outstanding and a float of 126.0m shares. Trading volume was 137,292 shares and has experienced an average volume of 47,620 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for MorphoSys AG was -0.72 which ended on 31st of December 2017.
Below was the last reported quarterly earnings per share:
Base on our calculations, the intrinsic value per share is 19.37, which means it might overvalued by -45.72%
Indicators Also to Watch:
Based on the latest filings, there is 15.70% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.
I calculated the beta to be 1.86
SeekingAlpha: Luther Burbank EPS in-line, misses on revenue
Based on last reported financials, the company’s return on equity is -6.10%, return on assets is -5.51%, profit margin is -29.22%, price-to-sales is 40.27 and price-to-book is 6.29.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result